2024-03-29T06:23:46Z
https://tsukuba.repo.nii.ac.jp/oai
oai:tsukuba.repo.nii.ac.jp:02001668
2022-04-27T09:50:27Z
2780:1789
3:62:5592:7432
Adjuvant therapy with nivolumab versus ipilimumab after complete resection of stage III/IV melanoma: Japanese subgroup analysis from the phase 3 CheckMate 238 study
Yokota, Kenji
Uchi, Hiroshi
Uhara, Hisashi
Yoshikawa, Shusuke
Takenouchi, Tatsuya
Inozume, Takashi
Ozawa, Kentaro
Ihn, Hironobu
藤澤, 康弘
フジサワ, ヤスヒロ
FUJISAWA, Yasuhiro
Qureshi, Anila
de Pril, Veerle
Otsuka, Yasushi
Weber, Jeffrey
Yamazaki, Naoya
The multinational phase 3 CheckMate 238 trial compared adjuvant therapy with nivolumab versus ipilimumab among patients with resected stage III or IV melanoma (N = 906). In this Japanese subgroup analysis of CheckMate 238 (n = 28; nivolumab, n = 18; ipilimumab, n = 10), both the 12- and 18-month recurrence-free survival rates were 56% for nivolumab and 30% for ipilimumab (hazard ratio, 0.66; 97.56% confidence interval, 0.19–2.24; P = 0.4390). No new safety signals were reported for Japanese patients. Results were consistent with those from the CheckMate 238 global population, indicating that nivolumab has the potential to be a treatment option for Japanese patients with resected melanoma who are at high risk of recurrence.
journal article
Wiley
2019-12
application/pdf
Journal of dermatology
12
46
1197
1201
0385-2407
AA00696658
https://tsukuba.repo.nii.ac.jp/record/2001668/files/JD_46-12-1197.pdf
eng
31638282
https://doi.org/10.1111/1346-8138.15103
© 2019 The Authors. The Journal of Dermatology published by John Wiley & Sons Australia, Ltd on behalf of Japanese Dermatological Association. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
open access